[{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"GW Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ GW Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ GW Pharmaceutical"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Weston Brain Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Weston Brain Institute","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Weston Brain Institute"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Substance Abuse and Mental Health Services Administration (SAMHSA)","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Substance Abuse and Mental Health Services Administration (SAMHSA)","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopkins University \/ Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor||CB1\/CB2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor||CB1\/CB2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Algorithme Pharma Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tetra BioPharma \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Tetra BioPharma \/ Algorithme Pharma Inc."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pellet","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor||CB1\/CB2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harmony Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Harmony Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Growlab Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH AFRICA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Growlab Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Growlab Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Growlab Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Pengajar Universiti Putra Malaysia","sponsor":"UPM Consultancy & Services Sdn. Bhd. | Pure Life Collective Pte Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"MALAYSIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Hospital Pengajar Universiti Putra Malaysia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hospital Pengajar Universiti Putra Malaysia \/ UPM Consultancy & Services Sdn. Bhd. | Pure Life Collective Pte Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Hospital Pengajar Universiti Putra Malaysia \/ UPM Consultancy & Services Sdn. Bhd. | Pure Life Collective Pte Ltd"},{"orgOrder":0,"company":"Akumentis Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Akumentis Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Akumentis Healthcare \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Akumentis Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Akumentis Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Akumentis Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Akumentis Healthcare \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Akumentis Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Zenara Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zenara Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zenara Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zenara Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Split, School of Medicine","sponsor":"Lexaria Bioscience | University of British Columbia | University of Colorado, Denver","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CROATIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"University of Split, School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Split, School of Medicine \/ Lexaria Bioscience | University of British Columbia | University of Colorado, Denver","highestDevelopmentStatusID":"6","companyTruncated":"University of Split, School of Medicine \/ Lexaria Bioscience | University of British Columbia | University of Colorado, Denver"},{"orgOrder":0,"company":"Palacky University","sponsor":"CB21 Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CZECH REPUBLIC","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"Palacky University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Palacky University \/ CB21 Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Palacky University \/ CB21 Pharma"},{"orgOrder":0,"company":"UAB Institut de Neuroci\u00e8ncies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"UAB Institut de Neuroci\u00e8ncies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UAB Institut de Neuroci\u00e8ncies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"UAB Institut de Neuroci\u00e8ncies \/ Undisclosed"},{"orgOrder":0,"company":"Loughborough University","sponsor":"Bridge Farm Nurseries Limited, Spalding, UK","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Loughborough University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loughborough University \/ Bridge Farm Nurseries Limited, Spalding, UK","highestDevelopmentStatusID":"1","companyTruncated":"Loughborough University \/ Bridge Farm Nurseries Limited, Spalding, UK"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Royal DSM \/ Nutrasource","highestDevelopmentStatusID":"6","companyTruncated":"Royal DSM \/ Nutrasource"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Vectura Ltd \/ Incannex Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Ltd \/ Incannex Healthcare"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Wellcome Trust | GW Pharmaceutical | Myonex | Cambridge Cognition | Premier Research Group | Diagram | Cambridgeshire and Peterborough NHS Foundation Trust | Oxford Health NHS Foundation Trust | West London NHS Trust | University of Augsburg | Charite Uni","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Oxford \/ Wellcome Trust | GW Pharmaceutical | Myonex | Cambridge Cognition | Premier Research Group | Diagram | Cambridgeshire and Peterborough NHS Foundation Trust | Oxford Health NHS Foundation Trust | West London NHS Trust | University of Augsburg | Charite Uni","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Wellcome Trust | GW Pharmaceutical | Myonex | Cambridge Cognition | Premier Research Group | Diagram | Cambridgeshire and Peterborough NHS Foundation Trust | Oxford Health NHS Foundation Trust | West London NHS Trust | University of Augsburg | Charite Uni"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":7.2000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":7.2000000000000002,"dosageForm":"Solution","sponsorNew":"GW Pharmaceutical \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sciensus Rare","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sciensus Rare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sciensus Rare \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sciensus Rare \/ MGC Pharmaceuticals"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":7.2000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":7.2000000000000002,"dosageForm":"Solution","sponsorNew":"GW Pharmaceutical \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"Ananda Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Ananda Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ananda Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ananda Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Argent BioPharma","sponsor":"Sputnik Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Argent BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Argent BioPharma \/ Sputnik Enterprises","highestDevelopmentStatusID":"6","companyTruncated":"Argent BioPharma \/ Sputnik Enterprises"},{"orgOrder":0,"company":"Argent BioPharma","sponsor":"Sputnik Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Argent BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Argent BioPharma \/ Sputnik Enterprises","highestDevelopmentStatusID":"6","companyTruncated":"Argent BioPharma \/ Sputnik Enterprises"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tetra Pharm Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tetra Pharm Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tetra Pharm Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Cannassure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Expanded Collaboration","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Cannassure Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lipidor AB \/ Cannassure Therapeutics"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Cannassure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Cannassure Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lipidor AB \/ Cannassure Therapeutics"},{"orgOrder":0,"company":"Avextra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avextra","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avextra \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avextra \/ Undisclosed"},{"orgOrder":0,"company":"Reakiro","sponsor":"A2W Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"POLAND","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Reakiro","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reakiro \/ A2W Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Reakiro \/ A2W Pharma"},{"orgOrder":0,"company":"Ananda Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Ananda Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ananda Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ananda Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bazelet Nehushtan LtD.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bazelet Nehushtan LtD.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bazelet Nehushtan LtD. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bazelet Nehushtan LtD. \/ Undisclosed"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Podiatry","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Innocan Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Hebrew University of Jerusalem"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Sustained Release","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Sustained Release","sponsorNew":"Innocan Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innocan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Sustained Release","sponsorNew":"Innocan Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innocan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Sustained Release","sponsorNew":"Innocan Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innocan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"SciSparc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Undisclosed"},{"orgOrder":0,"company":"SciSparc","sponsor":"Soroka Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Soroka Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Soroka Medical Center"},{"orgOrder":0,"company":"SciSparc","sponsor":"The Sheba Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ The Sheba Fund","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ The Sheba Fund"},{"orgOrder":0,"company":"SciSparc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Undisclosed"},{"orgOrder":0,"company":"SciSparc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Undisclosed"},{"orgOrder":0,"company":"SciSparc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Undisclosed"},{"orgOrder":0,"company":"SciSparc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Undisclosed"},{"orgOrder":0,"company":"SciSparc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Undisclosed"},{"orgOrder":0,"company":"SciSparc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Undisclosed"},{"orgOrder":0,"company":"SciSparc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Undisclosed"},{"orgOrder":0,"company":"SciSparc","sponsor":"Negev Autism Center Soroka University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Negev Autism Center Soroka University Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Negev Autism Center Soroka University Medical Center"},{"orgOrder":0,"company":"SciSparc","sponsor":"Soroka Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Soroka Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Soroka Medical Center"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Pill","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"Stero Biotechs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Stero Biotechs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stero Biotechs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stero Biotechs \/ Undisclosed"},{"orgOrder":0,"company":"Stero Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Stero Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stero Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stero Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Univo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Univo Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite BioPharma \/ Univo Pharmaceuticals"},{"orgOrder":0,"company":"Stero Biotechs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Stero Biotechs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stero Biotechs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Stero Biotechs \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Univo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Univo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Can-Fite BioPharma \/ Univo Pharmaceuticals"},{"orgOrder":0,"company":"Auburn University","sponsor":"Folium Biosciences | FutureCeuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Auburn University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Auburn University \/ Folium Biosciences | FutureCeuticals","highestDevelopmentStatusID":"1","companyTruncated":"Auburn University \/ Folium Biosciences | FutureCeuticals"},{"orgOrder":0,"company":"Defined Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Defined Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Defined Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Defined Research \/ Undisclosed"},{"orgOrder":0,"company":"Rejuva Medical Aesthetics","sponsor":"HealMD","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Rejuva Medical Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Rejuva Medical Aesthetics \/ HealMD","highestDevelopmentStatusID":"6","companyTruncated":"Rejuva Medical Aesthetics \/ HealMD"},{"orgOrder":0,"company":"Silkiss Eye Surgery","sponsor":"Benign Essential Blepharospasm Research Foundation | GW Pharmaceutical | Smith-Kettlewell Eye Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Silkiss Eye Surgery","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Silkiss Eye Surgery \/ Benign Essential Blepharospasm Research Foundation | GW Pharmaceutical | Smith-Kettlewell Eye Research Institute","highestDevelopmentStatusID":"9","companyTruncated":"Silkiss Eye Surgery \/ Benign Essential Blepharospasm Research Foundation | GW Pharmaceutical | Smith-Kettlewell Eye Research Institute"},{"orgOrder":0,"company":"Yale University","sponsor":"Connecticut Pharmaceutical Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Connecticut Pharmaceutical Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Yale University \/ Connecticut Pharmaceutical Solutions"},{"orgOrder":0,"company":"Yale University","sponsor":"VA Connecticut Healthcare System | National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ VA Connecticut Healthcare System | National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Yale University \/ VA Connecticut Healthcare System | National Institute on Drug Abuse"},{"orgOrder":0,"company":"University of South Florida","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"University of South Florida","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of South Florida \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of South Florida \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"McMaster University","sponsor":"MediPharm Labs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"McMaster University \/ MediPharm Labs","highestDevelopmentStatusID":"10","companyTruncated":"McMaster University \/ MediPharm Labs"},{"orgOrder":0,"company":"Universit\u00e9 de Sherbrooke","sponsor":"Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Universit\u00e9 de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Universit\u00e9 de Sherbrooke \/ Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke","highestDevelopmentStatusID":"8","companyTruncated":"Universit\u00e9 de Sherbrooke \/ Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke"},{"orgOrder":0,"company":"Universit\u00e9 de Sherbrooke","sponsor":"Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Universit\u00e9 de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Universit\u00e9 de Sherbrooke \/ Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke","highestDevelopmentStatusID":"8","companyTruncated":"Universit\u00e9 de Sherbrooke \/ Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"St. Joseph's Healthcare Hamilton \/ McMaster University"},{"orgOrder":0,"company":"Gefion Canada","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Gefion Canada","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gefion Canada \/ KGK Science","highestDevelopmentStatusID":"6","companyTruncated":"Gefion Canada \/ KGK Science"},{"orgOrder":0,"company":"The University of British Columbia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"The University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of British Columbia \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"The University of British Columbia \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Charlotte's Web","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Johns Hopkins University \/ Charlotte's Web","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopkins University \/ Charlotte's Web"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Cultivate Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johns Hopkins University \/ Cultivate Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopkins University \/ Cultivate Biologics"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Substance Abuse and Mental Health Services Administration | Canopy Growth Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Substance Abuse and Mental Health Services Administration | Canopy Growth Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopkins University \/ Substance Abuse and Mental Health Services Administration | Canopy Growth Corporation"},{"orgOrder":0,"company":"McLean Hospital","sponsor":"Massachusetts Life Sciences Center","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"McLean Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Solution","sponsorNew":"McLean Hospital \/ Massachusetts Life Sciences Center","highestDevelopmentStatusID":"8","companyTruncated":"McLean Hospital \/ Massachusetts Life Sciences Center"},{"orgOrder":0,"company":"University of Nebraska Medical Center","sponsor":"Ananda Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Nebraska Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Nebraska Medical Center \/ Ananda Scientific","highestDevelopmentStatusID":"8","companyTruncated":"University of Nebraska Medical Center \/ Ananda Scientific"},{"orgOrder":0,"company":"University of Nebraska","sponsor":"Ananda Scientific | University of Texas at Austin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Nebraska","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Nebraska \/ Ananda Scientific | University of Texas at Austin","highestDevelopmentStatusID":"8","companyTruncated":"University of Nebraska \/ Ananda Scientific | University of Texas at Austin"},{"orgOrder":0,"company":"NextEvo Inc.","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"NextEvo Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NextEvo Inc. \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"1","companyTruncated":"NextEvo Inc. \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"National Institute on Drug Abuse | International Center for Health Outcomes and Innovation Research | Brains Bioceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ National Institute on Drug Abuse | International Center for Health Outcomes and Innovation Research | Brains Bioceutical","highestDevelopmentStatusID":"10","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ National Institute on Drug Abuse | International Center for Health Outcomes and Innovation Research | Brains Bioceutical"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Solace Brands, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Patch","sponsorNew":"Northwell Health \/ Solace Brands, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Northwell Health \/ Solace Brands, Inc."},{"orgOrder":0,"company":"Northwell Health","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Northwell Health \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Main Line Health","sponsor":"Ananda Hemp","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Main Line Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Main Line Health \/ Ananda Hemp","highestDevelopmentStatusID":"8","companyTruncated":"Main Line Health \/ Ananda Hemp"},{"orgOrder":0,"company":"Pure Green","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Pure Green","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pure Green \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pure Green \/ Undisclosed"},{"orgOrder":0,"company":"Pure Green","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pure Green","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pure Green \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pure Green \/ Undisclosed"},{"orgOrder":0,"company":"Eastern Virginia Medical School","sponsor":"Old Dominion University | Ananda Hemp","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Eastern Virginia Medical School","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Eastern Virginia Medical School \/ Old Dominion University | Ananda Hemp","highestDevelopmentStatusID":"8","companyTruncated":"Eastern Virginia Medical School \/ Old Dominion University | Ananda Hemp"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Brains Bioceutical","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Brains Bioceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Brains Bioceutical \/ Icahn School of Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Brains Bioceutical \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lexaria Bioscience \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Can-Fite BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lexaria Bioscience \/ Can-Fite BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Can-Fite BioPharma"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"MediPharm Labs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ MediPharm Labs","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ MediPharm Labs"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Lyotropic Delivery Systems","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ananda Scientific \/ Lyotropic Delivery Systems","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Lyotropic Delivery Systems"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ananda Scientific \/ NYU Langone Health","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ NYU Langone Health"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"University Of Nebraska Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ananda Scientific \/ University Of Nebraska Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ University Of Nebraska Medical Center"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"180 Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"180 Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avata Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ZYUS Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Quolet Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Quolet Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quolet Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Quolet Industries \/ Undisclosed"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Receptor Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Receptor Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Bryden Stokes Limited","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Bryden Stokes Limited","highestDevelopmentStatusID":"4","companyTruncated":"Avicanna \/ Bryden Stokes Limited"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Applied Research Centre at Langara College","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Applied Research Centre at Langara College","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Applied Research Centre at Langara College"},{"orgOrder":0,"company":"Cronos Group","sponsor":"Geocann","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Technology","graph2":"Undisclosed","graph3":"Cronos Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cronos Group \/ Geocann","highestDevelopmentStatusID":"1","companyTruncated":"Cronos Group \/ Geocann"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Sera Labs","sponsor":"Cure Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sera Labs","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Cream","sponsorNew":"Sera Labs \/ Cure Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sera Labs \/ Cure Pharmaceutical"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder","sponsorNew":"Ananda Scientific \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"UCLA Jonsson Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder","sponsorNew":"Ananda Scientific \/ UCLA Jonsson Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ UCLA Jonsson Comprehensive Cancer Center"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tilray","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Tilray","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Tilray"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Harmony Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Harmony Biosciences"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jay Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Jay Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Jay Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Jay Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Bio-Gate AG","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Avicanna \/ Bio-Gate AG","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Bio-Gate AG"},{"orgOrder":0,"company":"Entourage Health","sponsor":"Irwin Naturals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Entourage Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Gel","sponsorNew":"Entourage Health \/ Irwin Naturals","highestDevelopmentStatusID":"15","companyTruncated":"Entourage Health \/ Irwin Naturals"},{"orgOrder":0,"company":"Veristat","sponsor":"PreveCeutical Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Veristat \/ PreveCeutical Medical","highestDevelopmentStatusID":"4","companyTruncated":"Veristat \/ PreveCeutical Medical"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Harmony Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Harmony Biosciences"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Harmony Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Entourage Health","sponsor":"NordicCan","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Entourage Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"Entourage Health \/ NordicCan","highestDevelopmentStatusID":"15","companyTruncated":"Entourage Health \/ NordicCan"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Institutional Review Board","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Funding","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Institutional Review Board","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Institutional Review Board"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Sycamore BioPharma","sponsor":"Branded Legacy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sycamore BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Sycamore BioPharma \/ Branded Legacy","highestDevelopmentStatusID":"15","companyTruncated":"Sycamore BioPharma \/ Branded Legacy"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"University of Montreal Hospital Research Centre","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tetra BioPharma \/ University of Montreal Hospital Research Centre","highestDevelopmentStatusID":"6","companyTruncated":"Tetra BioPharma \/ University of Montreal Hospital Research Centre"},{"orgOrder":0,"company":"Panag Pharma","sponsor":"True North Cannabis Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Panag Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Panag Pharma \/ True North Cannabis Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Panag Pharma \/ True North Cannabis Corp."},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Funding","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"MediPharm Labs","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Liquid","sponsorNew":"MediPharm Labs \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"MediPharm Labs \/ National Institutes of Health"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Safety Shot \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Safety Shot \/ Undisclosed"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Safety Shot \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Safety Shot \/ Undisclosed"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Safety Shot \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Safety Shot \/ Undisclosed"},{"orgOrder":0,"company":"Tilray","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oil","sponsorNew":"Tilray \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Undisclosed"},{"orgOrder":0,"company":"HempMeds","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BRAZIL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"HempMeds","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oil","sponsorNew":"HempMeds \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"HempMeds \/ Undisclosed"},{"orgOrder":0,"company":"HempMeds","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"HempMeds","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"HempMeds \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"HempMeds \/ Undisclosed"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oil","sponsorNew":"MediPharm Labs \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ McMaster University"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oil","sponsorNew":"MediPharm Labs \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ McMaster University"},{"orgOrder":0,"company":"Aurora Cannabis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurora Cannabis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Aurora Cannabis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aurora Cannabis \/ Undisclosed"},{"orgOrder":0,"company":"PAO Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"PAO Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"PAO Group \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"PAO Group \/ Undisclosed"},{"orgOrder":0,"company":"PAO Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"PAO Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"PAO Group \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"PAO Group \/ Undisclosed"},{"orgOrder":0,"company":"The Valens Company","sponsor":"PMI Mexico","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"The Valens Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil","sponsorNew":"The Valens Company \/ PMI Mexico","highestDevelopmentStatusID":"1","companyTruncated":"The Valens Company \/ PMI Mexico"},{"orgOrder":0,"company":"Leading Edge Pharms","sponsor":"Evio Labs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Leading Edge Pharms","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Leading Edge Pharms \/ Evio Labs","highestDevelopmentStatusID":"15","companyTruncated":"Leading Edge Pharms \/ Evio Labs"},{"orgOrder":0,"company":"Greene Street Pharmaceuticals","sponsor":"Verdepharmhealth","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Greene Street Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Greene Street Pharmaceuticals \/ Verdepharmhealth","highestDevelopmentStatusID":"4","companyTruncated":"Greene Street Pharmaceuticals \/ Verdepharmhealth"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pill","sponsorNew":"180 Life Sciences \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"4","companyTruncated":"180 Life Sciences \/ Hebrew University of Jerusalem"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Granite Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Granite Point Capital","highestDevelopmentStatusID":"7","companyTruncated":"Receptor Life Sciences \/ Granite Point Capital"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Receptor Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Receptor Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Receptor Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"CSIRO","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ CSIRO","highestDevelopmentStatusID":"7","companyTruncated":"Receptor Life Sciences \/ CSIRO"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Virpax Pharmaceuticals \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pharmaceuticals \/ Innovation Pharmaceuticals"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Nanomerics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Virpax Pharmaceuticals \/ Nanomerics","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pharmaceuticals \/ Nanomerics"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Thinkequity","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Virpax Pharmaceuticals \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pharmaceuticals \/ Thinkequity"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Ananda Scientific | National Center for Complementary and Integrative Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"NYU Langone Health \/ Ananda Scientific | National Center for Complementary and Integrative Health","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Ananda Scientific | National Center for Complementary and Integrative Health"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"NYU Grossman School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Ananda Scientific \/ NYU Grossman School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ NYU Grossman School of Medicine"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Ananda Scientific \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Ananda Scientific \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Lyotropic Delivery Systems","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Ananda Scientific \/ Lyotropic Delivery Systems","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Lyotropic Delivery Systems"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"ZYUS Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EmpowerPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"EmpowerPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"EmpowerPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EmpowerPharm \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Greenwich Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Greenwich Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Greenwich Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EmpowerPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"EmpowerPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"EmpowerPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EmpowerPharm \/ Undisclosed"},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"Radius Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Benuvia Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Solution","sponsorNew":"Benuvia Therapeutics \/ Radius Health","highestDevelopmentStatusID":"8","companyTruncated":"Benuvia Therapeutics \/ Radius Health"},{"orgOrder":0,"company":"Avicanna","sponsor":"University Health Network","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Avicanna \/ University Health Network","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ University Health Network"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Radius Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Radius Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EmpowerPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"EmpowerPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"EmpowerPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EmpowerPharm \/ Undisclosed"},{"orgOrder":0,"company":"Radius Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Radius Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pressure BioSciences","sponsor":"Cr\u00e8me de Canna","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pressure BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pressure BioSciences \/ Cr\u00e8me de Canna","highestDevelopmentStatusID":"15","companyTruncated":"Pressure BioSciences \/ Cr\u00e8me de Canna"},{"orgOrder":0,"company":"Pressure BioSciences","sponsor":"Somalab","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pressure BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pressure BioSciences \/ Somalab","highestDevelopmentStatusID":"15","companyTruncated":"Pressure BioSciences \/ Somalab"},{"orgOrder":0,"company":"Sipp Industries","sponsor":"SinuSave","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sipp Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sipp Industries \/ SinuSave","highestDevelopmentStatusID":"15","companyTruncated":"Sipp Industries \/ SinuSave"},{"orgOrder":0,"company":"PreveCeutical Medical","sponsor":"Endosane Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"PreveCeutical Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"PreveCeutical Medical \/ Endosane Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"PreveCeutical Medical \/ Endosane Pharmaceuticals"},{"orgOrder":0,"company":"Tilray","sponsor":"Aphria","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Strip","sponsorNew":"Tilray \/ Aphria","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Aphria"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Orcosa","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NYU Langone Health \/ Orcosa","highestDevelopmentStatusID":"9","companyTruncated":"NYU Langone Health \/ Orcosa"},{"orgOrder":0,"company":"Pure Green Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Pure Green Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pure Green Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pure Green Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Artelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"JOS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ JOS Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ JOS Pharmaceuticals"},{"orgOrder":0,"company":"Canntab Therapeutics","sponsor":"MediPharm Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Canntab Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Canntab Therapeutics \/ MediPharm Labs","highestDevelopmentStatusID":"15","companyTruncated":"Canntab Therapeutics \/ MediPharm Labs"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Orcosa","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"NYU Langone Health \/ Orcosa","highestDevelopmentStatusID":"9","companyTruncated":"NYU Langone Health \/ Orcosa"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Brockman Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Brockman Foundation","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Brockman Foundation"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"James Madison University","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ James Madison University","highestDevelopmentStatusID":"8","companyTruncated":"Canopy Growth Corporation \/ James Madison University"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"NM Clinical Research & Osteoporosis Center","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ NM Clinical Research & Osteoporosis Center","highestDevelopmentStatusID":"6","companyTruncated":"Canopy Growth Corporation \/ NM Clinical Research & Osteoporosis Center"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediPharm Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ Undisclosed"},{"orgOrder":0,"company":"City of Hope","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Undisclosed"},{"orgOrder":0,"company":"Salzman Group","sponsor":"Kalytera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Salzman Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salzman Group \/ Kalytera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Salzman Group \/ Kalytera Therapeutics"},{"orgOrder":0,"company":"Biopharmaceutical Research Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Biopharmaceutical Research Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biopharmaceutical Research Company \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biopharmaceutical Research Company \/ Undisclosed"},{"orgOrder":0,"company":"CanaQuest Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"CanaQuest Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanaQuest Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CanaQuest Medical \/ Undisclosed"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"GB Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"GB Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GB Sciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"GB Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tilray","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tilray \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tilray \/ Undisclosed"},{"orgOrder":0,"company":"Tilray","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tilray \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Undisclosed"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avata Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avata Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avata Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Aureuspharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZYUS Life Sciences \/ Aureuspharma","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Aureuspharma"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZYUS Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZYUS Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"PureForm","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"PureForm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureForm \/ Enveric Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"PureForm \/ Enveric Biosciences"},{"orgOrder":0,"company":"Aurora Cannabis","sponsor":"Vectura Fertin Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aurora Cannabis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurora Cannabis \/ Vectura Fertin Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Aurora Cannabis \/ Vectura Fertin Pharma"},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"Health Canada","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dalton Pharma Services","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dalton Pharma Services \/ Health Canada","highestDevelopmentStatusID":"15","companyTruncated":"Dalton Pharma Services \/ Health Canada"},{"orgOrder":0,"company":"PAO Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"PAO Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PAO Group \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PAO Group \/ Undisclosed"},{"orgOrder":0,"company":"CV Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"CV Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CV Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CV Science \/ Undisclosed"},{"orgOrder":0,"company":"Orcosa","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Orcosa","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orcosa \/ NYU Langone Health","highestDevelopmentStatusID":"7","companyTruncated":"Orcosa \/ NYU Langone Health"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GenBio","sponsor":"Strainsforpains","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"GenBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenBio \/ Strainsforpains","highestDevelopmentStatusID":"5","companyTruncated":"GenBio \/ Strainsforpains"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyMD Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyMD Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Vella Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Vella Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vella Bioscience \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Vella Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Artelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"South West Sydney Local Health District","sponsor":"University of Sydney | Lambert Initiative for Cannabinoid Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"South West Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"South West Sydney Local Health District \/ University of Sydney | Lambert Initiative for Cannabinoid Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"South West Sydney Local Health District \/ University of Sydney | Lambert Initiative for Cannabinoid Therapeutics"},{"orgOrder":0,"company":"Gold Coast Hospital and Health Service","sponsor":"Bod Australia","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Gold Coast Hospital and Health Service","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Gold Coast Hospital and Health Service \/ Bod Australia","highestDevelopmentStatusID":"11","companyTruncated":"Gold Coast Hospital and Health Service \/ Bod Australia"},{"orgOrder":0,"company":"Tiamat Australia Pty Ltd","sponsor":"Ananda Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tiamat Australia Pty Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiamat Australia Pty Ltd \/ Ananda Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Tiamat Australia Pty Ltd \/ Ananda Pharma"},{"orgOrder":0,"company":"Avecho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avecho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avecho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avecho \/ Undisclosed"},{"orgOrder":0,"company":"Bod Australia","sponsor":"Woolcock Institute of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Bod Australia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bod Australia \/ Woolcock Institute of Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Bod Australia \/ Woolcock Institute of Medical Research"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Avecho","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2025","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avecho","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Avecho \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Avecho \/ Sandoz B2B"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Curia","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Incannex Healthcare \/ Curia","highestDevelopmentStatusID":"6","companyTruncated":"Incannex Healthcare \/ Curia"},{"orgOrder":0,"company":"Elixinol Wellness","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Elixinol Wellness","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Elixinol Wellness \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Elixinol Wellness \/ Undisclosed"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Oberon Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"MGC Pharmaceuticals \/ Oberon Capital","highestDevelopmentStatusID":"15","companyTruncated":"MGC Pharmaceuticals \/ Oberon Capital"},{"orgOrder":0,"company":"Laboratorio Elea Phoenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ARGENTINA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Laboratorio Elea Phoenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorio Elea Phoenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorio Elea Phoenix \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Israelita Albert Einstein","sponsor":"Industria Farmac\u00eautica Health Meds","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Hospital Israelita Albert Einstein","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Israelita Albert Einstein \/ Industria Farmac\u00eautica Health Meds","highestDevelopmentStatusID":"9","companyTruncated":"Hospital Israelita Albert Einstein \/ Industria Farmac\u00eautica Health Meds"},{"orgOrder":0,"company":"FG Brasil","sponsor":"3F Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BRAZIL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"FG Brasil","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FG Brasil \/ 3F Clinical Trials","highestDevelopmentStatusID":"9","companyTruncated":"FG Brasil \/ 3F Clinical Trials"},{"orgOrder":0,"company":"Breath of Life International Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Breath of Life International Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Drops","sponsorNew":"Breath of Life International Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Breath of Life International Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CannaMore Biotechs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"CannaMore Biotechs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"CannaMore Biotechs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CannaMore Biotechs \/ Undisclosed"},{"orgOrder":0,"company":"Christopher Bell","sponsor":"Caliper Foods","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Christopher Bell","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Christopher Bell \/ Caliper Foods","highestDevelopmentStatusID":"1","companyTruncated":"Christopher Bell \/ Caliper Foods"},{"orgOrder":0,"company":"Elizabeth Donner","sponsor":"Jazz Pharmaceuticals | Alberta Children's Hospital | BC Children's Hospital Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Elizabeth Donner","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Elizabeth Donner \/ Jazz Pharmaceuticals | Alberta Children's Hospital | BC Children's Hospital Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"Elizabeth Donner \/ Jazz Pharmaceuticals | Alberta Children's Hospital | BC Children's Hospital Research Institute"},{"orgOrder":0,"company":"Anne Comi","sponsor":"Jazz Pharmaceuticals | Faneca 66 Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Anne Comi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anne Comi \/ Jazz Pharmaceuticals | Faneca 66 Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Anne Comi \/ Jazz Pharmaceuticals | Faneca 66 Foundation"},{"orgOrder":0,"company":"Yasmin Hurd","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Yasmin Hurd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yasmin Hurd \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Yasmin Hurd \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Dr. Paul Lyons","sponsor":"Biopharmaceutical Research Company","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Dr. Paul Lyons","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Paul Lyons \/ Biopharmaceutical Research Company","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Paul Lyons \/ Biopharmaceutical Research Company"},{"orgOrder":0,"company":"Timothy L. Brown","sponsor":"National Highway Traffic Safety Administration | Acclaro Research Solutions | Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Timothy L. Brown","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Timothy L. Brown \/ National Highway Traffic Safety Administration | Acclaro Research Solutions | Cognitive Research Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Timothy L. Brown \/ National Highway Traffic Safety Administration | Acclaro Research Solutions | Cognitive Research Corporation"},{"orgOrder":0,"company":"Pharma 5","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"MOROCCO","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pharma 5","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharma 5 \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharma 5 \/ Undisclosed"},{"orgOrder":0,"company":"Shaare Zedek Scientific Ltd.\u00a0","sponsor":"Greater Cannabis Company","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Shaare Zedek Scientific Ltd.\u00a0","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shaare Zedek Scientific Ltd.\u00a0 \/ Greater Cannabis Company","highestDevelopmentStatusID":"1","companyTruncated":"Shaare Zedek Scientific Ltd.\u00a0 \/ Greater Cannabis Company"},{"orgOrder":0,"company":"Delphian Therapeutics Australia Pty, Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Delphian Therapeutics Australia Pty, Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delphian Therapeutics Australia Pty, Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Delphian Therapeutics Australia Pty, Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Alasht Pharmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Alasht Pharmed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alasht Pharmed \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alasht Pharmed \/ Undisclosed"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"GW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"GW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Avextra","sponsor":"German Pain Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Avextra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avextra \/ German Pain Association","highestDevelopmentStatusID":"1","companyTruncated":"Avextra \/ German Pain Association"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Cannvalate","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Aerosol","sponsorNew":"Tetra BioPharma \/ Cannvalate","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Cannvalate"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cure Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Cure Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cure Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Exhale Wellness","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Exhale Wellness","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Exhale Wellness \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Exhale Wellness \/ Undisclosed"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Akanda Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Tetra BioPharma \/ Akanda Corp","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Akanda Corp"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Tetra BioPharma \/ Alpha Blue Ocean","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Alpha Blue Ocean"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Tetra BioPharma \/ Alpha Blue Ocean","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Alpha Blue Ocean"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Cannvalate","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Tetra BioPharma \/ Cannvalate","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Cannvalate"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Tilray","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tilray \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Undisclosed"},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Greenwich Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Greenwich Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Greenwich Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Greenwich Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Greenwich Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Greenwich Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"European Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediPharm Labs \/ European Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"MediPharm Labs \/ European Pharmaceutical"},{"orgOrder":0,"company":"Avicanna","sponsor":"Ei.Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avicanna \/ Ei.Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Ei.Ventures"},{"orgOrder":0,"company":"MAKScientific","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"MAKScientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAKScientific \/ Tetra BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"MAKScientific \/ Tetra BioPharma"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"Medlab Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Medlab Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Medlab Clinical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medlab Clinical \/ Undisclosed"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"||CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"MediPharm Labs \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediPharm Labs \/ Undisclosed"},{"orgOrder":0,"company":"Indication BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"||HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Indication BioScience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indication BioScience \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Indication BioScience \/ Undisclosed"},{"orgOrder":0,"company":"CV Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nicotine","moa":"||Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"CV Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CV Science \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CV Science \/ Undisclosed"},{"orgOrder":0,"company":"Dalriada Drug Discovery","sponsor":"Champignon","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"||Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Dalriada Drug Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dalriada Drug Discovery \/ Champignon","highestDevelopmentStatusID":"4","companyTruncated":"Dalriada Drug Discovery \/ Champignon"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Lucy Scientific Discovery","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Psilocybine","moa":"||Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Lucy Scientific Discovery","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Health \/ Lucy Scientific Discovery"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||Serotonin 2a (5-HT2a) receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Wesana Health \/ Undisclosed"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Lucy Scientific Discovery","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Psilocybine","moa":"||Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Lucy Scientific Discovery","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Health \/ Lucy Scientific Discovery"},{"orgOrder":0,"company":"Maps Laboratories Private Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"||SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Maps Laboratories Private Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Maps Laboratories Private Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maps Laboratories Private Limited \/ Undisclosed"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Cannabidiol","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Kingswood Investments","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Kingswood Investments"},{"orgOrder":0,"company":"The Valens Company","sponsor":"Valens Company","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Agreement","leadProduct":"Capsaicin","moa":"||Vanilloid receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"The Valens Company","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Cream","sponsorNew":"The Valens Company \/ Valens Company","highestDevelopmentStatusID":"15","companyTruncated":"The Valens Company \/ Valens Company"}]

Find Clinical Drug Pipeline Developments & Deals for (-)-Cannabidiol

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Cannabinoid oral solution has received approval for the treatment of several neurological disorders. It functions by stimulating two receptors, cannabinoid receptor type 1 and type 2, within the endocannabinoid system, maintaining body's homeostatis.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          May 15, 2023

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Biophore CB

                          02

                          Details : Under the terms of the agreement, Vectura will undertake formulation screening studies, manufacturing process optimisation studies and stability assessments, as well as manufacturing a laboratory-scale batch of IHL-216A (Cannabidiol) to support toxicolog...

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          June 22, 2021

                          Lead Product(s) : Cannabidiol,Isoflurane

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Preclinical

                          Sponsor : Incannex Healthcare

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Skyepharma Company Banner

                          03

                          Icahn School of Medicine at Mount Sinai

                          Country arrow
                          OPRD
                          Not Confirmed

                          Icahn School of Medicine at Mount Sinai

                          Country arrow
                          OPRD
                          Not Confirmed

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase III

                          Sponsor : National Institute on Drug Abuse | International Center for Health Outcomes and Innovation Research | Brains Bioceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Cannabidiol is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Opioid-Related Disorders.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          April 23, 2025

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : National Institute on Drug Abuse | International Center for Health Outcomes and Innovation Research | Brains Bioceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : ZYN002 is the first-and-only pharmaceutically manufactured synthetic cannabidiol devoid of THC and formulated for the treatment of Fragile X Syndrome.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          April 08, 2025

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Nantheia ATL5 is an investigational drug that combines cannabidiol with ANANDA’s proprietary Liquid Structure delivery technology, being developed for smoking cessation.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          October 22, 2024

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Nantheia ATL5 is an investigational drug that combines cannabidiol with ANANDA’s proprietary Liquid Structure delivery technology, being developed for smoking cessation.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          October 22, 2024

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : UCLA Jonsson Comprehensive Cancer Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Nantheia ATL5, an investigational drug using cannabidiol (CBD), leveraging ANANDA’s proprietary delivery technology, for its potential efficacy in treating co-occurring OUD and chronic pain.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          October 15, 2024

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : The Company intends to use the proceeds for research and clinical development of its pipeline includling, AVCN583601 (Cannabidiol), for the treatment of epidermolysis bullosa.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          August 28, 2024

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $1.9 million

                          Deal Type : Private Placement

                          blank

                          09

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : 180 Life Sciences evaluated the uptake of cannabidiol (CBD) in a solid formulation which can be delivered as a pill orally for the treatment of epilepsy.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          July 30, 2024

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Trichomylin softgels, a first-in-class drug product candidate formulated with a proprietary fixed-dose cannabinoid combination, has been specifically designed for the management of chronic pain.

                          Product Name : Trichomylin

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          July 30, 2024

                          Lead Product(s) : Cannabidiol,Cannabichromene,Tetrahydrocannabinol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank